Endovenous laser ablation for great saphenous varicose veins

Asser Abd El Hamid Goda*

INTRODUCTION

Varicose veins affect 25-40 per cent of the adult population.1-3 The majority of varicose veins are due to saphenofemoral and great saphenous vein (GSV) incompetence.4 Conventional surgery involves Stripping of the GSV combined with high ligation. This is usually performed as a day-case procedure and with a 2-3 weeks recovery period.5 Recently, as alternatives to conventional surgery minimally invasive endovenous techniques have been developed which have a potential advantages in form of low postoperative morbidity and a short recovery period.6 Endovenous laser ablation (EVLA) is the most commonly used minimally invasive endovenous procedure.7 EVLA acts by releasing thermal energy to the venous wall and to the blood, causing localized tissue damage. High patient satisfaction and relative simplicity have made this procedure popular.8

The aim of this study was to assess the efficacy and safety of EVLA for treatment of varicose veins in a 12 months follow-up.

METHODS

This prospective study was carried out in private hospitals between January 2017 and August 2018. All patients gave their formal consent. The study included patients age 21-55 years, with symptomatic primary varicose veins; with Clinical Etiologic Anatomic Pathophysiological (CEAP) class C2-C4, and reflux (a reflux time of more than 0.5 s on duplex Imaging) in the GSV 5-10 mm in diameter. In this study we excluded patients who have history of previous surgical interventions in the groin area with the exception of inguinal herniotomy or anterior or posterior accessory saphenous vein incompetence or small saphenous vein insufficiency requiring treatment at the same limb.
**Technique**

All interventions were carried out under general anaesthesia or light sedative before (diazepam) and during (alfentanil, propofol) the procedure in an operating theatre. Access to the great saphenous vein is achieved at the ankle or just below the knee, by either 18-G needle puncture or the stab wound-Mueller hook approach.

Under duplex guidance, J-tip guide wire (diameter of 0.035 inch), a 5F-angio catheter was advanced proximally till reach close to the sapheno-femoral junction (SFJ). Then, perivascular tumescent local anesthesia was infiltrated along the length of the vein using 50 ml 1 per cent lidocaine with 1:200,000 adrenaline (epinephrine) and 8.4 mg bicarbonate in 1000 ml (normal saline) to treat and dissipate the heat. After that, the guide wire was then replaced by a 600-micron laser fiber with an outer diameter of 1.0 mm and the position of the laser fiber tip was confirmed by duplex scanning 1 to 2 cm distal to the SFJ.

Lastly, the laser fiber connected to 810-nm diode laser source (EVLT; Diomed, Andover, Massachusetts, USA) and the veins were treated by using pulse mode. The power delivered with 1-s laser pulses and 1-s intervals between pulses. During each interval the laser fiber was withdrawn 2-3 mm.

The energy delivered was 10-14 W at the thigh, reduced to about 6 W at the level of the knee where the vein tends to lie superficially in the subcutaneous tissue, and 4 to 6 W at the lower leg.

Immediately after the procedure in the operating theatre, the patency of the deep veins was checked in all patients by the operating surgeon using duplex ultrasonography. After treatment no-stretch compression bandage application applied for 1 week, followed by a grade II compression stocking for a further week day and night.

On the day of surgery and the first postoperative day, all patients received thromboprophylaxis consisting of 20 to 40 mg of enoxaparin. At time of discharge all patients instructed to take analgesia only if required in form of paracetamol (1 g up to four times a day) and ibuprofen (400 mg up to three times a day) and to mobilize as much as possible.

**Assessments and follow up**

The patients attended follow-up at 7 days, 1, 3, 6 and 12 months postoperatively. At every follow-up visit, clinical examination and duplex ultrasonography were done for every patient to assess the effectiveness and safety of EVLA.

The effectiveness outcome of EVLA assessed by duplex ultrasonography and clinical examination. Duplex ultrasonography detects the abolition of reflux (reflux was defined as a retrograde flow lasting more than 0.5 s) after calf compression in the saphenous vein, and detect the degree of GSV occlusion either complete or partial or no occlusion. (Treatment failure is defined as an open part of the treated vein segment ≥5 cm in length). Clinical examination evaluates the patients by VCSS to detect symptom severity before treatment, and after 6 and 12 months.⁹

The safety of EVLA assessed by clinical examination to detect its complications at 7 days, 1, 3, 6 and 12 months.

**Statistical analysis**

We calculated mean values using the Excel 2003 statistics part.

**RESULTS**

Between January 2017 and August 2018, 27 patients (35 limbs) with varicose vein met the inclusion criteria and were enrolled in the current series (Table 1).

**Table 1: Baseline characteristics of the study patients.**

| Patients (no.) | 27 |
|---|---|
| Legs (no.) | 35 |
| **Patient demographics** | | |
| Age | 39.1⃰ (21-55) |
| Sex | ♀ 17 (77.1%) |
| **Limb characteristics** | | |
| N (%) | | |
| Rt side | 15 (42.8) |
| C class (CEAP classification) | | |
| C2 | 20 (57.1) |
| C3 | 9 (25.7) |
| C4 | 6 (17.1) |

Value is the mean. ♂-Male, ♀-Female.

**The treatment effectiveness**

Duplex ultrasonography during the follow-ups, at 1 week after the operation revealed the abolish of reflux and complete occlusion in the main trunk of the great saphenous vein was 33/35 (94.3%). At 1, 3, 6, 12 month after the operation, abolish of reflux and complete occlusion in the main trunk of the great saphenous vein was 34/35 (97.1%) (Table 2).

**Table 2: Postoperative duplex follow up results.**

| Trunk blood flow signal | 1 week | 1 month | 3 months | 6 months | 12 months |
|---|---|---|---|---|---|
| | 2 | 1 | 1 | 1 | 1 |

Clinical examination evaluating the patients by VCSS at 6 and 12 months revealed improvement of the mean...
VCSS scores significantly after the procedure where the mean VCSS scores declined from 7.76±1.49 at the baseline to 2.67±1.32 at 6 months (p<0.001) and to 2.59±1.03 at 12 months (p<0.001) (Table 3).

Table 3: Improvement of the mean VCSS scores.

| Mean VCSS | At baseline | At 6 months | At 12 months | P value |
|-----------|-------------|-------------|--------------|---------|
| 7.76±1.49 | 2.67±1.32   | 2.59±1.03   | <0.001       |

DISCUSSION

The role of minimally invasive varicose vein treatments increase due to increase the patients demand. EVLA has been established as a minimally invasive varicose vein treatment alternative to saphenous vein stripping surgery. Many studies reported that EVLA is a safe and effective means of treating GSV reflux. This article describes our experience on treating GSV reflux using EVLA. In the present study, the occlusion rate of GSV using EVLA was 97% at 6 and 12 months that confirm the results which reported in other studies.

Darwood et al reported that GSV reflux at 3 months was abolished in 41 of 42 (97.6%) legs treated with EVLA in randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins.

Koramaz et al reported in retrospective nonrandomized study evaluated treatment of GSV of 339 patients with either nontumescent n-butyl cyanoacrylate versus endovenous laser therapy that the occlusion rate of GSV which treated with EVLA was 97.3% at one year.

Rasmussen et al reported that the occlusion rate of GSV using EVLA was (93% (95-92)) at one year, in randomized clinical trial including 500 patients (580 legs) comparing endovenous laser ablation, radiofrequency, foam sclerotherapy, and surgical stripping.

Hamann et al reported in randomized clinical trial including 450 patients with GSV varicosities which were treated with either RVLA or RFA that the occlusion rate of patients who treated with EVLA was 95% at one year.

Hodenberg et al reported that the occlusion rate of varicose vein at one year was 99.6% of the treated 308 limbs with endovenous laser ablation using 1470 nm diode laser with a radial fiber.

Liu et al reported in study evaluated the efficacy of endovenous laser treatment combined with sclerosing foam in treating 186 lower limbs with varicose veins that the occlusion rate of GSV was 100% at 6 months.

In the present study the mean VCSS scores improved significantly after the procedure, similar to that reported in other trials. The VCSS score improvement confirms that the treatment is efficacious.

In the present study, no skin burn, DVT, or PE were detected during follow up. Pigmentation was detected in 3 patients at 1 week and 1 month follow up, but at 3 months, pigmentation was still present in one patient only which disappeared at 6 months. Local hematomata was detected in one patient at 1 week follow up but it disappeared in the following follow up. Paresthesia was observed in one patient during follow up at 1st week, 1 month and 3 months but it disappeared at 6 months. The complications in our study are comparable to that reported by some authors and also, are different than that reported by some others.

Liu et al reported that pigmentation occurred in 30 patients, within 1 week and 1 month after the operation, while at 3 months after the operation, pigmentation was found in 15 patients. Within 6 months after the operation, pigmentation in the surgical site had not completely disappeared in six patients. Local hematomata occurred in two patients at 1 week after the operation, saphenous nerve injury occurred in five patients. Within 3 months after the operation, however, these disappeared at 6 months.
months after the operation. None of the patients developed deep vein thrombosis and pulmonary embolism. The complications of EVLA in Liu et al study are comparable to that observed in our study taking in mind the difference in number of study patients in each of 2 studies.19

Hodenberg et al reported that no DVT or PE were detected during follow up. Local hematoma was detected in 18 patients, paresthesia in one patient, phlebitis in 3 patients at 1 week follow up but all these complications disappeared at one year follow up. The difference between our study and Hodenberg study in the complication of EVLA which may be explained by the difference in the type of laser where, in our study we used 810-nm laser, which targets the blood in the vein because laser light of this wavelength is predominantly absorbed by hemoglobin that make this type of laser has a good hemostatic effect but Hodenbeg used 1470 nm laser which acts directly on the vessel wall through absorption of interstitial water but not hemoglobin.18

Koramaz et al reported that the patients experienced burning, pigmentation, and bruising, 2.12%, 5.82%, and 2.65% respectively in the first week, but these conditions resolved by the 6-month follow-up. In 1.59% of the patients, paresthesia was observed and resolved within 6 months. Phlebitis was observed in 7.94% of the patients. DVT was diagnosed in 1.59% of the patients. There is a difference between our study and Koramaz et al study in the complication of EVLA which may be explained by the difference in the type of laser where Koramaz used 1470 nm laser and also, he did not give us details on the amount and the constituent of the tumescent anesthesia that he used.15

CONCLUSION

EVLA is an effective and safe procedure for the treatment of varicose great saphenous veins. It is considered a new armamentarium that is added to the treatment modalities of great saphenous varicose veins.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Evans CJ, Fowkes FG, Buckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. Epidemiol Community Health 1999;53:149-53.
2. Rabe E, Berboth G, Pannier F. [Epidemiology of chronic venous diseases.] Wien Med Wochenschr 2016;166:260-3.
3. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. VCP coordinators. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31:105-15.
4. Lahropoulos N, Leon M, Nicolaides AN, Giannoukas AD, Volteas N, Chan P. Superficial venous insufficiency: correlation of anatomic extent of reflex with clinical symptoms and signs. J Vasc Surg. 1994;20:953-8.
5. Vaislic C, Clerc PCG, Dan J, de Tilly I, Escalard JM, Gosselin J et al. Return to work after surgical treatment of varicosities of the lower limb. Phlebology. 1992;45:159-65.
6. Darwood RJ, Theivacumar N, Dellagrammaticas D, Mavor AID, Gough MJ. Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins. Br J Surg. 2008;95:294-301.
7. Kluner C, Fischer T, Filimonow S, Hamm B, Kroncke T. Endovenous treatment of primary varicose veins: an effective and safe therapeutic alternative to stripping? Rofo, 2005;177:179-87.
8. Puggioni A, Kalra M, Carmo M, Mozes G, Gloviczki P, Rochester, et al. Endovenous laser therapy and radiofrequency ablation of the great saphenous vein: Analysis of early efficacy and complications. J Vasc Surg. 2005;42:488-93.
9. Rutherford RB, Padberg FT, Comerota AJ, Kistner RL, Meissner MH, Moneta GL. Venous severity scoring:an adjunct to venous outcome assessment. J Vasc Surg. 2000;31:1307-12.
10. Kanwar A, Harsans M, Lees T, Stansby G. Trends in varicose vein therapy in England: radical changes in the last decade. Ann R Coll Surg Engl. 2010;92:341-6.
11. Kalteis M, Berger I, Messie-Werndl, Pistrich R, Schimetta W, Pölz W, et al. High ligation combined with stripping and endovenous laser ablation of the great saphenous vein:Early results of a randomized controlled study. J Vasc Surg. 2008;47:822-9.
12. Vahaaaho S, Halmsen,ki K, Alback A, E, Saarinen E, Venermo M. Five-year follow-up of a randomized clinical trial comparing open surgery, foam sclerotherapy and endovenous laser ablation for great saphenous varicose veins. BJS. 2018;105:686-91.
13. Perkowski P, Ravi R, Gowda R, Olsen D, Ramaiyah V, Rodriguez-Lopez J, et al. Endovenous laser ablation of the saphenous vein for treatment of venous insufficiency and varicose veins:early results from a large single-center experience. J Endovasc Ther. 2004;11:132-8.
14. Min RJ, Khilnani N, Zimmert SE. Endovenous laser treatment of saphenous vein reflux:long-term results. J Vasc Interv Radiol. 2003;14:991-6.
15. Koramaz I, El Kılıç H, Gökalp F, Bitargil M, Bektas N, Engin E, et al. Ablation of the great saphenous vein with nontumescent n-butyl cyanoacrylate versus endovenous laser therapy. J Vasc Surg Venous Lymphat Disord. 2017;5(2):210-5.
16. Rasmussen LH, Lawaetz M, Bjoern L, Vennits B, Blemings A, Eklof B. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg. 2011;98:1079-87.

17. Hamann S, Timmer-de Mik L, Fritschy WM, Kuiters GRR, Nijsten TEC, van den Bos RR. Randomized clinical trial of endovenous laser ablation versus direct and indirect radiofrequency ablation for the treatment of great saphenous varicose veins. BJS. 2019;106:998-1004.

18. Von Hodenberg E, Zerweck C, Knittel M, Zeller T, Schwarz T. Endovenous laser ablation of varicose veins with the 1470 nm diode laser using a radial fiber - 1-year follow-up. Phlebology. 2015;30(2):86-90.

19. Liu Z, Guo P, Zhang L, Shi M, Wang R, Meng Q. Efficacy of Endovenous Laser Treatment Combined with Sclerosing Foam in Treating Varicose Veins of the Lower Extremities. Adv Ther. 2019;36:2463-74.

Cite this article as: Goda AAEH. Endovenous laser ablation for great saphenous varicose veins. Int Surg J 2019;6:4502-6.